Recon: HHS plans to cut 10,000 jobs across department; FDA having difficulty meeting product reviews after layoffs

• RFK Jr. Plans 10,000 Job Cuts in Major Restructuring of Health Department (WSJ) (STAT)
• Exclusive: FDA staff struggle to meet product review deadlines after DOGE layoffs (Reuters)
• Vaccine critic’s apparent selection to head HHS autism study shocks experts (STAT)
• US FDA approves first treatment for rare genetic disorder Prader-Willi syndrome (Reuters)
• AbbVie, J&J to add proprietary data to AI protein model in bid to accelerate drug discovery (STAT)
• Republicans’ plan to cut government spending is hitting a major snag: Medicaid (STAT)
• Trump turbulence stalls large pharma and biotech deals, bankers say (Reuters)
• U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine (WSJ)
• Targeting FDA user fees would leave agency gutted, experts say (Roll Call)

• GSK taps into UK health data for dementia study (Pharmaphorum)
• UK's Starmer heads for test of health strategy as Reform gains ground (Reuters)
• KKR nears deal to buy Japanese medical gear maker Topcon, sources say (Reuters)
• This Canadian company’s AI tool could help drugmakers cut risk in late-stage cancer trials (STAT)
• Bayer acquires rights in Puhe BioPharma cancer drug candidate (Reuters)

• Lilly adds Alzheimer's to online offerings (Reuters)
• Merck plans to  launch US subcutaneous version of Keytruda on October 1 (Reuters)
• Impatient about cell and gene therapy? Progress in biotech is not always linear (STAT)
• Burst PIPEs? So-so returns for biotech’s once-buzzy financing vehicle (STAT)
• Soleno Therapeutics’ ‘life-changing’ rare-disease drug approved (STAT)
• Study suggests mRNA vaccine could make humans resistant to ticks that transmit Lyme bacteria (STAT)
• Wave to submit Duchenne drug for approval after Phase 2 success (STAT)
• First gene-edited pig liver transplanted into a brain-dead person (STAT)
• Galatea Bio gets $25M to map genetic diversity of 10 million people, help pharma create new medicines (Endpoints)
• Candel to focus on non-squamous lung cancer following new survival data (Endpoints)
• Nkarta to lay off 34% of staff; Savara’s debt financing deal (Endpoints)
• Why Miga Health's co-founders decided to quit building (Endpoints)
• Aurion CEO is out as Alcon takes majority stake in cell therapy startup (Endpoints)

• New tests for Alzheimer’s and cancer get FDA’s ‘breakthrough’ status (STAT)
• Bausch + Lomb recalls some of its implantable eye lenses (Reuters)
• Recent pharma-telehealth partnerships feel ‘black boxy,’ and why that’s problematic (STAT)
• Financial returns and efficiency of AI scribes remain unclear, report finds (Endpoints)
• Research Finds Benefit From DME Suppliers For People Living With Diabetes (MedTech Insight)
• Dexcom’s FDA warning letter reveals unauthorized changes to sensors (MedTech Dive)

• Adios to Synthetic Colors in Food? (FDA Law Blog)
• FDA Releases Updated Food Allergen Guidance in Searchable Format; Removes Coconut From Major Food Allergens (Food Safety)

• On NIH director’s first day, the agency tackles one of his priorities — ending ‘censorship’ in science (STAT)
• Tara Schwetz, who oversaw creation of ARPA-H, placed on leave by NIH (STAT)
• Trump administration says it will pull back billions in Covid funding from local health departments (STAT)
• US pulls back $12 billion in funding to state health departments (Reuters)
• Trump healthcare price transparency order may not bring intended relief to patients (Reuters)